Annovis Bio Inc ANVS 深 沪
已收盘 04-02 16:00:00 美东时间
2.28
+0.160
+7.55%
华盛通- 最 高2.29
- 今 开2.06
- 成交量 96.26万股
- 最 低 2.03
- 昨 收 2.12
- 总市值 6465.00万
- 52周最高 5.50
- 市盈率 静 --
- 换手率 3.39%
- 52周最低 1.19
- 委 比 60.00%
- 总股本 2835.53万
- 历史最高 132.00
- 量 比 1.94
- 振 幅 12.26%
- 历史最低 1.11
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Annovis Bio Issued New U.S. Patent For Prevention And Treatment Of Neurological Injuries From Brain Infections
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's
04-02 19:31
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries Annovis Bio secured U.S. Patent No. 12,582,632 B2 covering use of buntanetap to prevent or treat neurological injuries linked to brain infections. Patent claims include preventive use in at-risk healthy individuals
04-02 19:30
Annovis Publishes Historical Review of Buntanetap in The Scientist
Annovis Bio, Inc. (NYSE: ANVS) announced the publication of an article in *The Scientist* detailing the history and development of buntanetap, its lead drug candidate for neurodegenerative diseases like Alzheimer's and Parkinson's. The article traces buntanetap's journey from its 19th-century origins through its current Phase 3 clinical trials, with 70% of early Alzheimer's patients enrolled. Buntanetap is also being tested in an open-label Parki...
03-31 12:00
Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial
Annovis Bio partners with NeuroRPM for AI wearable monitoring in Parkinson’s trial Annovis partnered with NeuroRPM to use NeuroRPM’s FDA-cleared wearable platform for digital biomarker monitoring in Annovis’s ANVS-25002 open-label Parkinson’s disease clinical trial. The NeuroRPM platform uses Apple
03-19 19:31
Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study
Annovis Bio partners with NeuroRPM to deploy FDA-cleared AI digital biomarkers in Parkinson’s study Annovis partnered with NeuroRPM to deploy an FDA-cleared AI platform for movement-data collection in an ongoing Parkinson’s disease study. The platform is intended to monitor bradykinesia, tremor, and
03-19 19:31
Annovis Bio shares are trading higher. The company reported Q4 financial results.
Annovis Bio shares are trading higher. The company reported Q4 financial result...
03-17 00:38
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.34) by 13.7 percent. This is a 9.3 percent increase over losses of $(0.43) per share from the same
03-16 19:33
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Bio在2025年取得重要进展，启动了治疗早期阿尔茨海默病的关键III期临床试验，并扩大了帕金森病的开放标签扩展研究。公司公布了积极的生物标志物数据，显示药物buntanetap具有潜在的疾病修饰作用。此外，公司加强了管理团队，扩展了知识产权，并通过股票发行增加了现金流。尽管净亏损增加，但公司预计现金储备足以支持至2026年第三季度的运营。
03-16 11:30
Annovis Bio to Present Twice at AD/PD 2026 International Conference
Annovis Bio to Present Twice at AD/PD 2026 International Conference Annovis Bio Inc. will attend the AD/PD 2026 International Conference, held March 17-21, 2026, in Copenhagen, Denmark, where it plans two presentations highlighting clinical data on buntanetap in Parkinson’s disease and an update on
03-03 21:02
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
Annovis Bio, a Phase 3 clinical-stage biotechnology company, announced its participation in the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026) in Copenhagen, Denmark. The company will present two studies on its investigational oral therapy, buntanetap, focusing on its effects in Parkinson’s disease (PD) and early Alzheimer’s disease (AD). Presentation #1 will discuss buntanetap's impact on cognition and biomar...
03-03 13:00
